The effect of peripheral enzyme inhibitors on levodopa concentrations in blood and CSF

Movement Disorders

Volumn 25, Issue 3, 2010, Pages 363-367

  Nord, Maria ^a   Zsigmond, Peter ^a   Kullman, Anita ^a   Årstrand, Kerstin ^a   Dizdar, Nil ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

COMT; Continuous infusion; Levodopa; Parkinson's disease

Indexed keywords

CARBIDOPA; ENTACAPONE; LEVODOPA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID DRAINAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSATE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFECT; FEMALE; HUMAN; LUMBAR SPINAL CORD; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; PARKINSON DISEASE; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; AREA UNDER CURVE; CATECHOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; LEVODOPA; MALE; MEPIVACAINE; MICRODIALYSIS; MIDDLE AGED; NITRILES; PARKINSON DISEASE; TIME FACTORS;

EID: 77649135487     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22613     Document Type: Article

References (30)

1. Fiorentini C, Rizzetti MC, Busi C, et al. Loss of synaptic D1 dopamine/ N-methyl-D-aspartate glutamate receptor complexes in LDOPA-induced dyskinesia in the rat. Mol Pharmacol 2006;69: 805-812.
2. de la Fuente-Fernandez R, Schulzer M, Mak E, Calne DB, Stoessl AJ. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 2004;127 (Part 4): 888-899.
3. Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 1988;24: 366-371.
4. Deuschl G, Vaitkus A, Fox GC, Roscher T, Schremmer D, Gordin A. Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off. Mov Disord 2007;22:1550-1555.
5. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409-2417.
6. Thomas A, Bonanni L, Di Iorio A, et al. End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease. J Neurol 2006;253:1633-1639.
7. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123 (Part 11):2297-2305.
8. Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J 2007;83:384-388.
9. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007;22:1379-1389; quiz1523.
10. Mouradian MM, Heuser IJ, Baronti F, Chase TN. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27: 18-23.
11. Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002;125 (Part 9):2058-2066.
12. Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-910.
13. Heikkinen H, Nutt JG, LeWitt PA, Koller WC, Gordin A. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease. Clin Neuropharmacol 2001;24:150-157.
14. Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;68:589-594.
15. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
16. Heikkinen H, Varhe A, Laine T, et al. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. Br J Clin Pharmacol 2002;54:363-371.
17. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.
18. Kaakkola S, Teravainen H, Ahtila S, Rita H, Gordin A. Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 1994;44: 77-80.
19. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 1996;19:283-296.
20. Merello M, Lees AJ, Webster R, Bovingdon M, Gordin A. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:186-189.
21. Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends Neurosci 2000;23 (10Suppl):S117-S126.
22. Dizdar N, Kullman A, Norlander B, Olsson JE, Kagedal B. Human pharmacokinetics of L-3,4-dihydroxyphenylalanine studied with microdialysis. Clin Chem 1999;45:1813-1820.
23. Chase TN, Baronti F, Fabbrini G, Heuser IJ, Juncos JL, Mouradian MM. Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989;39(11 Suppl 2):7-10; discussion 19.
24. Stocchi F, Olanow CW. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 2004; 62(1Suppl 1):S56-S63.
25. Olanow CW, Obeso JA. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. Neurology 2000;55 (11 Suppl 4):S72-S77; discussion S78-81.
26. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. Clin Neuropharmacol 1995;18:46-57.
27. Mizutani Y, Okada Y, Ogawa M, Hasegawa T, Nabeshima T. Pharmacokinetic model of oral levodopa and role of carbidopa in parkinsonian patients. Biol Pharm Bull 1995;18:1729-1737.
28. Nutt JG, Woodward WR, Anderson JL. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism. Ann Neurol 1985;18:537-543.
29. Leppert PS, Cortese M, Fix JA. The effects of carbidopa dose and time and route of administration on systemic L-dopa levels in rats. Pharm Res 1988;5:587-591.
30. Olanow CW, Gauger LL, Cedarbaum JM. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease. Ann Neurol 1991;29:556-559.